BLC
DGX icon

Brown, Lisle/Cummings’s Quest Diagnostics DGX Stock Holding History

Brown, Lisle/Cummings’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.16K Buy
+11
New +$2.14K ﹤0.01% 799

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Brown, Lisle/Cummings's DGX Position: Q1 2026 in Review

Brown, Lisle/Cummings opened a new position in Quest Diagnostics (DGX) in Q1 2026: 11 shares worth $2.16K. The stake represents ﹤0.01% of the portfolio and ranks #799 among its holdings.

1,069 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Brown, Lisle/Cummings held 11 shares of Quest Diagnostics worth $2.16K as of Q1 2026.
  • Quest Diagnostics was a new Brown, Lisle/Cummings position in Q1 2026.
  • Quest Diagnostics made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #799 holding.
  • 1,069 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.